Brand Name | Status | Last Update |
---|---|---|
hyzaar | New Drug Application | 2022-06-01 |
losartan potassium and hydrochlorothiazide | ANDA | 2024-01-11 |
losartan potassium and hydrochlorothiazide | ANDA | 2024-01-31 |
losartan potassium and hydrochlorothiazide losartan potassium hctz | ANDA | 2019-10-14 |
losartan potassium-hydrochlorothiazide | ANDA | 2010-09-16 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 14 | 21 | 45 | 53 | 21 | 150 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | 3 | 3 | 5 | 6 | 17 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 2 | 4 | 5 | 4 | 16 |
Essential hypertension | D000075222 | — | I10 | 1 | 3 | 6 | 5 | — | 15 |
Covid-19 | D000086382 | — | U07.1 | 1 | 6 | 5 | 3 | 1 | 14 |
Proteinuria | D011507 | HP_0000093 | R80 | — | 1 | 3 | 3 | 5 | 12 |
Chronic renal insufficiency | D051436 | — | N18 | — | 1 | 1 | 1 | 8 | 11 |
Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | 2 | 3 | 2 | 8 |
Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | — | 1 | 4 | 2 | 7 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 1 | 5 | 1 | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Marfan syndrome | D008382 | Orphanet_558 | Q87.4 | — | 2 | 7 | — | — | 9 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 3 | 1 | — | — | 4 |
Hyperlipidemias | D006949 | HP_0003077 | E78.5 | 1 | 1 | 1 | — | — | 3 |
Pneumonia | D011014 | EFO_0003106 | — | — | 1 | 1 | — | — | 2 |
Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | 1 | — | — | 2 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 2 | 1 | — | — | 2 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | 1 | — | 1 | 2 |
Pulmonary fibrosis | D011658 | — | J84.10 | 1 | 2 | 1 | — | — | 2 |
Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | 1 | — | 1 | 2 |
Overweight | D050177 | — | E66.3 | 1 | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 4 | — | — | — | 7 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 3 | — | — | — | 4 |
Neoplasms | D009369 | — | C80 | 1 | 2 | — | — | — | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
Morbid obesity | D009767 | EFO_0001074 | — | 1 | 1 | — | — | 2 | 3 |
Aging | D000375 | GO_0007568 | R41.81 | 1 | 2 | — | — | 1 | 3 |
Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 2 | — | — | 1 | 3 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | 1 | — | — | — | 2 |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 2 | — | — | — | 2 |
Fibrosis | D005355 | — | — | 1 | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 24 | — | — | — | 6 | 30 |
Drug interactions | D004347 | — | — | 3 | — | — | — | — | 3 |
Pre-eclampsia | D011225 | EFO_0000668 | O14 | 1 | — | — | — | — | 1 |
Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 2 | 2 |
Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | — | 1 | 1 |
Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | — | — | — | 1 | 1 |
Memory | D008568 | — | — | — | — | — | — | 1 | 1 |
Learning | D007858 | — | — | — | — | — | — | 1 | 1 |
Lupus nephritis | D008181 | EFO_0005761 | — | — | — | — | — | 1 | 1 |
Albuminuria | D000419 | EFO_0004285 | R80.9 | — | — | — | — | 1 | 1 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | — | 1 | 1 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Drug common name | Losartan |
INN | losartan |
Description | Losartan is a biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an endothelin receptor antagonist and an anti-arrhythmia drug. It is a biphenylyltetrazole and a member of imidazoles. It is a conjugate acid of a losartan(1-). |
Classification | Small molecule |
Drug class | angiotensin II receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1 |
PDB | — |
CAS-ID | 114798-26-4 |
RxCUI | — |
ChEMBL ID | CHEMBL191 |
ChEBI ID | 6541 |
PubChem CID | 3961 |
DrugBank | DB00678 |
UNII ID | JMS50MPO89 (ChemIDplus, GSRS) |